422 related articles for article (PubMed ID: 26960399)
21. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
22. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
[TBL] [Abstract][Full Text] [Related]
23. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
24. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
25. CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS.
Kumar G; Maria Z; Kohli U; Agasing A; Quinn JL; Ko RM; Zamvil SS; Axtell RC
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33649164
[TBL] [Abstract][Full Text] [Related]
26. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
27. Aging murine B cells have decreased class switch induced by anti-CD40 or BAFF.
Frasca D; Riley RL; Blomberg BB
Exp Gerontol; 2007 Mar; 42(3):192-203. PubMed ID: 17067770
[TBL] [Abstract][Full Text] [Related]
28. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
[TBL] [Abstract][Full Text] [Related]
29. Study on the Mechanism of Selective Interaction of BR3 and BCMA with BAFF and APRIL.
Li L; Jiang Y; Su L; Feng D; Wei J; Sun J
Protein Pept Lett; 2020; 27(11):1114-1123. PubMed ID: 32282294
[TBL] [Abstract][Full Text] [Related]
30. Engineering an APRIL-specific B cell maturation antigen.
Patel DR; Wallweber HJ; Yin J; Shriver SK; Marsters SA; Gordon NC; Starovasnik MA; Kelley RF
J Biol Chem; 2004 Apr; 279(16):16727-35. PubMed ID: 14764606
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor superfamily member (TNFSF) 13 (APRIL) and TNFSF13B (BAFF) downregulate homeostatic immunoglobulin production in the intestines.
Hashiguchi M; Kashiwakura Y; Kanno Y; Kojima H; Kobata T
Cell Immunol; 2018 Jan; 323():41-48. PubMed ID: 29100594
[TBL] [Abstract][Full Text] [Related]
32. Early Cytomegalovirus Reactivation in Renal Recipients Is Associated with High Levels of B Cell Maturation Antigen Transcript Expression Prior to Transplantation.
Alfaro R; Rodríguez-Aguilar L; Llorente S; Jimenez-Coll V; Martínez-Banaclocha H; Galián JA; Botella C; Moya-Quiles MR; Muro-Perez M; Minguela A; Legaz I; Muro M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445668
[TBL] [Abstract][Full Text] [Related]
33. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses.
Huntington ND; Tomioka R; Clavarino C; Chow AM; Liñares D; Maña P; Rossjohn J; Cachero TG; Qian F; Kalled SL; Bernard CC; Reid HH
Int Immunol; 2006 Oct; 18(10):1473-85. PubMed ID: 16914508
[TBL] [Abstract][Full Text] [Related]
34. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.
Alexaki VI; Pelekanou V; Notas G; Venihaki M; Kampa M; Dessirier V; Sabour-Alaoui S; Stathopoulos EN; Tsapis A; Castanas E
Endocrinology; 2012 Feb; 153(2):739-49. PubMed ID: 22166983
[TBL] [Abstract][Full Text] [Related]
35. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.
Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J
Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446
[TBL] [Abstract][Full Text] [Related]
36. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
37. Macrophage-derived BAFF induces AID expression through the p38MAPK/CREB and JNK/AP-1 pathways.
Kim HA; Seo GY; Kim PH
J Leukoc Biol; 2011 Mar; 89(3):393-8. PubMed ID: 21169521
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
39. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
Neri P; Kumar S; Fulciniti MT; Vallet S; Chhetri S; Mukherjee S; Tai Y; Chauhan D; Tassone P; Venuta S; Munshi NC; Hideshima T; Anderson KC; Raje N
Clin Cancer Res; 2007 Oct; 13(19):5903-9. PubMed ID: 17908986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
